MPI

General Information


DRACP ID  DRACP00146

Peptide Name   MPI

Sequence  IDWKKLLDAAKQIL

Sequence Length  14

UniProt ID  Not available

PubChem CID  Not available

Origin  Polybia paulista

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
K562 Blast phase chronic myelogenous leukemia, BCR-ABL10 positive; Chronic myeloid leukemia Leukemia IC50=5.06±0.1 µM MTT assay 24h 1
K562/ADM Blast phase chronic myelogenous leukemia, BCR-ABL17 positive; Chronic myeloid leukemia Leukemia IC50=7.01±1.4 µM MTT assay 24h 1
HL-60 Adult acute myeloid leukemia; Acute myeloid leukemia Leukemia IC50=5.86±0.18 µM MTT assay 24h 1
L1210 Mouse leukemia Leukemia IC50=6.18±0.53 µM MTT assay 24h 1
HepG2 Hepatoblastoma Blastoma IC50=25.2±1.8 µM MTT assay 24h 1
PC-3 Prostate carcinoma Carcinoma IC50=23.7±2.9 µM MTT assay 24h 1
EJ Endometrial Adenocarcinoma Carcinoma IC50=25±1.9 µM MTT assay 24h 1

Hemolytic Activity  Human erythrocytes: Not active up to 64 µM; 3.2% Hemolysis=25 µM; <1% Hemolysis=12.5 µM

Normal (non-cancerous) Cytotoxicity  Rat mast cells: 62% degranulation=100 µM; NIH 3T3: 50% Cell death>60 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP00146

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C78H131N19O20

Absent amino acids  CEFGHMNPRSTVY

Common amino acids  KL

Mass  188711

Pl  9.44

Basic residues  3

Acidic residues  2

Hydrophobic residues  8

Net charge  1

Boman Index  -908

Hydrophobicity  6.43

Aliphatic Index  153.57

Half Life 
  Mammalian: 2.8 hour
  Yeast: 10 min
  E.coli: 2 min

Extinction Coefficient cystines  5500

Absorbance 280nm  423.08

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 19233550

Title  Novel mode of action of polybia-MPI, a novel antimicrobial peptide, in multi-drug resistant leukemic cells

Doi 10.1016/j.canlet.2008.12.027

Year  2009

Literature 2

Pubmed ID 16129513

Title  Structural and functional characterization of two novel peptide toxins isolated from the venom of the social wasp Polybia paulista

Doi 10.1016/j.peptides.2005.04.026

Year  2005

Literature 3

Pubmed ID 20600424

Title  A novel analog of antimicrobial peptide Polybia-MPI, with thioamide bond substitution, exhibits increased therapeutic efficacy against cancer and diminished toxicity in mice

Doi 10.1016/j.peptides.2010.06.019

Year  2010

Literature 4

Pubmed ID 27900727

Title  Antimicrobial activity and stability of the D-amino acid substituted derivatives of antimicrobial peptide polybia-MPI

Doi 10.1186/s13568-016-0295-8

Year  2016

Literature 5

Pubmed ID 29075946

Title  Antimicrobial activity and stability of stapled helices of polybia-MP1

Doi 10.1007/s12272-017-0963-5

Year  2017

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.